NCT06238687: An ongoing trial by Tasly Pharmaceutical Group Co., Ltd
This trial is ongoing. It must report results 2 years from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06238687 |
|---|---|
| Title | A Phase I/IIa Study to Evaluate the Safety, Tolerability , Pharmacokinetics and Preliminary Efficacy of STRO-002 in Chinese Adults With Advanced Epithelial Ovarian Cancer, Endometrial Cancer, and Other Advanced Malignant Solid Tumors. |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Nov. 8, 2023 |
| Completion date | Dec. 30, 2026 |
| Required reporting date | Dec. 30, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |